Pharm Aid: Conjugated polysaccharide pentavalent vaccine against meningococcal disease

Main article: Vaccines in Russia

2023: Vaccine clinical trials begin

The Russian pharmaceutical The company Eid Farm"," a supplier of rotavirus, vaccines in the Russian Federation on February 22, 2023 announced the start of clinical trials of a pentavalent vaccine against meningococcal disease. The company received permission Ministry of Health of the Russian federation to conduct them on February 21, 2023. Earlier, the vaccine showed its effectiveness in laboratory and animal tests, as well as in foreign clinical trials on volunteers (about 4 thousand people).

Conjugated polysaccharide pentavalent vaccine protects against the world's most common meningococci, belonging to serogroups A, C, W, Y and X. Unlike other vaccines used in Russia against meningococcal disease, Pharm Eid includes an additional serotype X. It is a common agent of infection in China, Latin America, the Middle East, to which the UAE belongs, and is also found in some regions of the Russian Federation.

Clinical studies of the meningococcal vaccine will be carried out in stages. People of all ages, from adults to children aged 9-12 months, will take part in the study. The vaccine is administered intramuscularly.

Meningococcal disease is a very dangerous disease. The most effective proven way to prevent meningococcal disease remains vaccination of both the adult and child populations. Our company seeks to provide a wider coverage of the population with vaccine prophylaxis, and not only in serotypes A and C, but in serotypes X, W, Y, especially since population migration has intensified, ties with friendly states that are endemic according to these serotypes have been strengthened, "said Azamat Metov, CEO of Farm Aid. - We do everything to ensure that people in Russia get access to the most modern immunobiological preparations. Therefore, as part of the import substitution project, we have concluded agreements with the world's largest vaccine manufacturers from friendly countries. According to them, the company transfers technologies for the production of innovative biotechnological products from international partners to Russia. This format has already proven its effectiveness on the example of a vaccine for the prevention of rotavirus. Similarly, we work with other immunobiological drugs, the production of which is planned to be localized at our plant under construction in the Kaluga region.

Adolescents aged 13-17 and people over 60 are most susceptible to meningococcal infection - this information is provided in the decree of the chief state sanitary doctor of the Russian Federation of December 20, 2018.